Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2011 - 2026)

Neurocrine Biosciences' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.65 for Q1 2026.

• Quarterly Asset Utilization Ratio changed 0.14% year-over-year to 0.65 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.65 (changed 0.14% YoY) and the FY2025 annual result came in at 0.69, up 1.38% from the prior year.
• Asset Utilization Ratio was 0.65 for Q1 2026 at Neurocrine Biosciences, up from 0.64 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.67 in Q2 2023 and bottomed at 0.45 in Q2 2022.
• A 5-year average of 0.6 and a median of 0.64 in 2025 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio slipped 16.66% — and 2023, when it soared 48.76%.
• Neurocrine Biosciences' Asset Utilization Ratio stood at 0.5 in 2022, then gained by 23.48% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then decreased by 0.98% to 0.64 in 2025, then gained by 1.17% to 0.65 in 2026.
• Business Quant data shows NBIX's Asset Utilization Ratio at 0.65 in Q1 2026, 0.64 in Q4 2025, and 0.66 in Q3 2025.